Previous Close | 687.10 |
Open | 688.40 |
Bid | 678.60 x 0 |
Ask | 678.50 x 0 |
Day's Range | 677.40 - 691.20 |
52 Week Range | 441.50 - 742.20 |
Volume | |
Avg. Volume | 2,934,967 |
Market Cap | 3.026T |
Beta (5Y Monthly) | 0.19 |
PE Ratio (TTM) | 40.63 |
EPS (TTM) | 16.70 |
Earnings Date | Jan 31, 2024 |
Forward Dividend & Yield | 7.08 (1.03%) |
Ex-Dividend Date | Aug 18, 2023 |
1y Target Est | 715.28 |
Subscribe to Yahoo Finance Plus to view Fair Value for NOVO-B.CO
Pfizer expects the market for new obesity pills to be $90 billion per year. Lilly, Novo, and many biotechs hope to claim chunks of it.
Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.